Targeting TTR amyloidosis at its source.

Phil, 71, retired; ATTRwt-CM patient

Transthyretin (TTR) amyloidosis is a family of rare, devastating diseases with serious unmet medical needs. Eidos Therapeutics is working to change that by developing a novel therapeutic, AG10, that targets the disease at its source by stabilizing TTR.

Link to: PatientsLink to: Physicians